...

首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Incidence and Outcomes of Primary Engraftment Failure in Patients Undergoing Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis

【24h】

Incidence and Outcomes of Primary Engraftment Failure in Patients Undergoing Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis

机译：降低强度条件的同种异体造血干细胞移植治疗原发性骨髓纤维化的患者原发性移植失败的发生率和结果

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation》 |2016年第1期|共1页
作者
Partain Daniel K.; Damlaj Moussab; Litzow Mark R.; Al-kali Aref; Hogan William J.; Hashmi Shahrukh K.; Gangat Naseema; Foran James; Slack James L.; Palmer Jeanne; Mesa Ruben A.; Patnaik Mrinal S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. Incidence and Outcomes of Primary Engraftment Failure in Patients Undergoing Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis [J] . Partain Daniel K., Damlaj Moussab, Litzow Mark R., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2016,第3Suppla1期

机译：降低强度条件的同种异体造血干细胞移植治疗原发性骨髓纤维化的患者原发性移植失败的发生率和结果
2. Impact of ATG Dose on the Outcome of Patients Undergoing Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies [J] . Cornillon Jerome, Balsat Marie, Cabrespine Aurelie, Acta Haematologica . 2016,第4期

机译：ATG剂量对降低强度条件后继发异基因造血干细胞移植治疗血液系统恶性肿瘤患者结果的影响
3. Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: Does donor T-cell engraftment 3 months after transplant predict survival? [J] . MachaczkaM., JohanssonJ.-E., RembergerM., Leukemia and lymphoma . 2012,第9期

机译：降低强度条件的异基因造血干细胞移植在瑞典治疗慢性淋巴细胞性白血病：移植后3个月的供体T细胞植入能否预测存活？
4. HIGH DOSE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR PATIENTS WITH PRIMARY SYSTEMIC AMYLOIDOSIS (AL): AN ABMTR STUDY [C] . DH Vesole, W Perez, D Reece, International Symposium on Amyloidosis . 2005

机译：具有自体造血干细胞移植（HSCT）的高剂量治疗用于初级全身淀粉样蛋白症（AL）的患者：ABMTR研究
5. Donor selection for patients undergoing allogeneic hematopoietic stem cell transplantation: Assessment of the priorities of Canadian hematopoietic stem cell transplant physicians. [D] . Tay, Jason. 2009

机译：接受同种异体造血干细胞移植的患者的供体选择：加拿大造血干细胞移植医生的优先事项评估。
6. Improved Outcomes Using Tacrolimus/Sirolimus for Graft Versus Host Disease prophylaxis with a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplant as treatment of Myelofibrosis [O] . David S. Snyder, Joycelynne Palmer, Karl Gaal, -1

机译：使用Tacrolimus / Sirolemus进行移植物与宿主疾病预防的改善的结果具有降低的强度调理方案用于同种异体造血细胞移植作为髓细胞的治疗
7. Incidence and Outcomes of Primary Engraftment Failure in Patients Undergoing Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis [O] . Daniel K. Partain, Moussab Damlaj, Mark R. Litzow, 2016

机译：经过强度调节强度造血干细胞移植对原发性肌纤维化的患者初生植入失败的发病率和结果

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号